layout.fixed.naaccr.doc.naaccr23.rxSummBrm.html Maven / Gradle / Ivy

Go to download

Show more of this group Show more artifacts with this name
Show all versions of layout Show documentation

Framework that allows defining file formats (layouts) and use them to read and write data files.

There is a newer version: 6.2


  
    Item #
    Length
    Source of Standard
    Year Implemented
    Version Implemented
    Year Retired
    Version Retired
  
  
    1410
    2
    SEER/CoC
    
    
    
    
  



NAACCR XML: Tumor.rxSummBrm


Alternate Names

   Biological Response Modifiers (pre-96 SEER)

   Immunotherapy (SEER/CoC)


Description
Records whether immunotherapeutic (biologic response modifiers) agents were administered as first-course treatment at all facilities or the reason they were not given. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host’s response to tumor cells. 
Rationale
Systemic therapy may involve the administration of one or a combination of agents. This data item allows for the evaluation of the administration of immunotherapeutic agents as part of the first course of therapy. 
Note: Prior to 2013, targeted therapies that invoke an immune response, such as Herceptin, had been coded as chemotherapy. Effective with cases diagnosed January 1, 2013, and forward these therapies are classified as biological response modifiers. Coding instructions for these changes have been added to the remarks field for the applicable drugs in the SEER*RX Interactive Drug Database (

http://seer.cancer.gov/tools/seerrx/). 
Codes (Refer to the most recent version  of STORE and the SEER Program Code Manual for additional instructions.) 
00 None, immunotherapy was not part of the planned first course of therapy.
01 Immunotherapy administered as first course therapy.
82 Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age).
85 Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86 Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was stated in the patient record.
87 Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88 Immunotherapy was recommended, but it is unknown if it was administered.
99 It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record; death certificate-only cases.
Note :For tumors diagnosed on or after January 1, 2003,  information on bone marrow transplants and stem cell transplants should  be coded in the new field, RX SUMM--Transplnt/Endocr [3250]. The CoC  standards for hospitals do not allow use of codes 02-06 in tumors  diagnosed on or after January 1, 2003.

00	None, immunotherapy was not part of the planned first course of therapy.
01	Immunotherapy administered as first course therapy.
82	Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (i.e., comorbid conditions, advanced age).
85	Immunotherapy was not administered because the patient died prior to planned or recommended therapy.
86	Immunotherapy was not administered. It was recommended by the patient's physician, but was not administered as part of first-course therapy. No reason was stated in the patient record.
87	Immunotherapy was not administered. It was recommended by the patient's physician, but this treatment was refused by the patient, the patient's family member, or the patient's guardian. The refusal was noted in the patient record.
88	Immunotherapy was recommended, but it is unknown if it was administered.
99	It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record; death certificate-only cases.